Format

Send to

Choose Destination
Expert Opin Biol Ther. 2009 Jun;9(6):677-88. doi: 10.1517/14712590902932897.

Cellular immunotherapy for ovarian cancer.

Author information

1
University of Arkansas for Medical Sciences, Department of Microbiology and Immunology, 4301 West Markham, Little Rock, AR 72205, USA. mjcannon@uams.edu

Abstract

BACKGROUND:

Ovarian cancer is frequently diagnosed at an advanced stage, and although initially responsive to surgery and chemotherapy, has a high rate of recurrence and mortality. Cellular immunotherapy may offer the prospect of treatment to prevent or delay recurrent metastatic disease.

OBJECTIVE:

To provide an overview of current innovations in cellular immunotherapy for ovarian cancer, with an emphasis on dendritic cell vaccination and adoptive T-cell immunotherapy.

METHODS:

Three key areas are explored in this review: first, an appraisal of the current state of the art of cellular immunotherapy for treatment of ovarian cancer; second, a discussion of the immunological defenses erected by ovarian cancer to prevent immunological attack, with an emphasis on the role of tumor-associated regulatory T cells; and third, an exploration of innovative techniques that may enhance the ability of cellular immunotherapy to overcome ovarian tumor-associated immune suppression.

RESULTS/CONCLUSION:

Ovarian cancer is recognized as a paradigm for tumor-associated immune suppression. Innovative approaches for antagonism of tumor-associated regulatory T-cell infiltration and redirection of self antigen-driven regulatory T-cell activation may provide the key to development of future strategies for cellular immunotherapy against ovarian cancer.

PMID:
19456205
PMCID:
PMC2718679
DOI:
10.1517/14712590902932897
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center